Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2

Recruiting N/A Interventional Study
PASC Post Acute Sequelae of COVID 19 Fatigue
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Study type
Interventional
Purpose
Basic Science
Participants needed
200 (estimated)
Sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc. · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This proposal aims to understand the neurobiological mechanisms of fatigue in individuals with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). This knowledge will eventually provide candidate mechanisms to target with pharmacological intervention and inform rehabilitative care for those individuals suffering from symptoms of fatigue in PASC.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age 18 to 75 years old. * Have received a clinical diagnosis of post-acute sequelae of SARS-CoV-2 (PASC)/long COVID syndrome using the criteria specified by Thaweethai, et al., 2023 (JAMA). This symptom checklist provides a score based on the number and severity of symptoms. A…
Contacts

Anthony Gonzalez

443-923-2716

gonzalezan@kennedykrieger.org

CONTACT

Vikram Chib, PhD

CONTACT